Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA
Apr04

Liveblogging First-Time Disclosures of Drug Structures from #ACSNOLA

Bookmark this page now, folks. On Wednesday, April 10, I will be here, liveblogging the public debut of five drug candidates’ structures. The “First Time Disclosures” Session at the ACS National Meeting in New Orleans runs from 2PM-4:55PM Central time. I am not able to conjure up a permalink to the session program, so here’s a screengrab instead. 1:20PM I’m in hall R02, where the session’s set to...

Read More
New developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 2
Mar01

New developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 2

The following is a guest post from Sally Church (known to many in the twittersphere as @MaverickNY), from the Pharma Strategy Blog. In my last post on The Haystack, we discussed the phase III data from the Abraxane MPACT trial in advanced pancreatic cancer that was presented at the recent ASCO GI meeting in San Francisco. Two other late-stage studies in pancreatic cancer caught my eye—fresh data for AB Science’s kinase inhibitor...

Read More
New Developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 1
Feb26

New Developments in Advanced Pancreatic Cancer from ASCO GI 2013 – Part 1

The following is a guest post from Sally Church (known to many in the twittersphere as @MaverickNY), from the Pharma Strategy Blog. The cancer research conference season kicked off in earnest in 2013 with the American Society of Clinical Oncology (ASCO)’s Gastrointestinal Symposium, held in San Francisco in late January. Some of the most anticipated data to be presented at ASCO GI was for drugs that treat pancreatic cancer, with three...

Read More
Rigged Reactions: Biocatalysis Meets 13C NMR
Jul19

Rigged Reactions: Biocatalysis Meets 13C NMR

When you think of reaction screening, what comes to mind? Most would say LC-MS, the pharma workhorse, which shows changes in molecular polarity, mass, and purity with a single injection. Some reactions provide conversion clues, like evolved light or heat. In rare cases, we can hook up an in-line NMR analysis – proton (1H) usually works best due to its high natural abundance (99.9%). Please welcome a new screening technique: 13C...

Read More
J&J Could Score Priority Review Voucher with Bedaquiline NDA
Jul02

J&J Could Score Priority Review Voucher with Bedaquiline NDA

Janssen Research and Development, part of J&J, has asked the FDA to approve bedaquiline, a diarylquinoline to treat multi-drug resistant tuberculosis. If given the green light, bedaquiline would be the first drug with a new mechanism of action to be approved for tuberculosis in over four decades. Janssen points out that the pill would also be the first drug approved for multi-drug resistant TB. If approved, Johnson & Johnson...

Read More
Tetrodotoxin: Why Toxic Is Complicated
May22

Tetrodotoxin: Why Toxic Is Complicated

(This post was written for the “Our Favorite Toxic Chemicals” blog carnival hosted by Sciencegeist.) It was a meal Captain James Cook would just as soon have forgotten. The fish, an unfamiliar species, seemed harmless enough. But after just a small taste of its liver, he and two shipmates regretted it. “We were seized with an extraordinary weakness in all our limbs attended with a numness [sic]…We each of us...

Read More